Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 11/20 | 0.79 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9010586 | 1.00 | VDR (0.79) | VDRCYP24A1 | |
| SCHEMBL19601388 | 1.00 | VDR (0.79) | VDRCYP24A1 | |
| SCHEMBL13665667 | 1.00 | VDR (0.79) | VDRCYP24A1 | |
| SCHEMBL861063 | 1.00 | VDR (0.79) | VDRCYP24A1 | |
| SCHEMBL12371707 | 0.95 | CYP24A1 (0.77) | VDRCYP24A1 | |
| SCHEMBL12641460 | 0.95 | CYP24A1 (0.77) | VDRCYP24A1 | |
| SCHEMBL14802244 | 0.95 | CYP24A1 (0.77) | VDRCYP24A1 | |
| SCHEMBL12190408 | 0.95 | CYP24A1 (0.77) | VDRCYP24A1 | |
| SCHEMBL22422513 | 0.95 | CYP24A1 (0.77) | VDRCYP24A1 | |
| SCHEMBL9070738 | 0.94 | VDR (0.71) | VDRCYP24A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188064-B2 | Reducing cell differentiation of adipocyte; reducing body fat | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188064-B2 | Reducing cell differentiation of adipocyte; reducing body fat | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-05-29 | — | — | US | disclosed |
| US-7745404-B2 | Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745404-B2 | Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-7566696-B2 | Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566696-B2 | Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7541348-B2 | 2-methylene-19-nor-(20S)-1α-hydroxy-trishomopregnacalciferol | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541348-B2 | 2-methylene-19-nor-(20S)-1α-hydroxy-trishomopregnacalciferol | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-06-02 | — | — | US | disclosed |
| US-20080146491-A1 | USE OF CALCITONIN AND CALCITONIN-LIKE PEPTIDES TO TREAT AND PREVENT MULTIPLE SCLEROSIS | DELUCA HECTOR F | 2008-06-19 | — | — | US | disclosed |
| US-20080146491-A1 | USE OF CALCITONIN AND CALCITONIN-LIKE PEPTIDES TO TREAT AND PREVENT MULTIPLE SCLEROSIS | DELUCA HECTOR F | 2008-06-19 | — | — | US | disclosed |
| US-20070105774-A1 | Administering an appropriate dosage schedule of a bone calcium resorption inhibitor like alendronate and a toxic dose of a vitamin D compounds like 1, alpha 25-dihydroxyvitamin D3 without developing hypercalcemia | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-05-10 | — | — | US | disclosed |
| US-20070105774-A1 | Administering an appropriate dosage schedule of a bone calcium resorption inhibitor like alendronate and a toxic dose of a vitamin D compounds like 1, alpha 25-dihydroxyvitamin D3 without developing hypercalcemia | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105774-A1 | Administering an appropriate dosage schedule of a bone calcium resorption inhibitor like alendronate and a toxic dose of a vitamin D compounds like 1, alpha 25-dihydroxyvitamin D3 without developing hypercalcemia | CALCA, CALCRL, CYP24A1 | VDR 7/4885CYP24A1 3/4885 |
| US-20080146491-A1 | USE OF CALCITONIN AND CALCITONIN-LIKE PEPTIDES TO TREAT AND PREVENT MULTIPLE SCLEROSIS | CALCA, CALCB, CALCRL | VDR 5/4885CYP24A1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.